Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients

Fuksiewicz, Małgorzata; Kamińska, Janina; Kotowicz, Beata; Kowalska, M; Rubach, Maryna

doi:10.1515/cclm.2006.192

Cited by 25 publications

(22 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly to our results, a previous study revealed that IL-1Ra levels were higher in patients with thyroid cancer (15). In normal cells, IL-1 secretion is mediated via inflammatory stimulation or cytokines, whereas tumor cells synthesize and secrete IL-1 through an autocrine mechanism.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer

Yiğit

Değirmencioğlu

Uğurlu

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Due to poor prognosis in advanced non-small cell lung cancer (NSCLC), new effective markers are required in the monitoring of the disease. The present study aimed to investigate the association between the serum IL-1 receptor antagonist (IL-1Ra) level, overall survival (OS), and treatment response in NSCLC, and to evaluate the usefulness of the serum IL-1Ra level as a prognostic marker for NSCLC. Eighty patients (72 men and 8 women) and 40 healthy volunteers (13 men and 27 women) were included in the present study. The median progression-free survival was 16 weeks for patients with high serum IL-1Ra levels, and 35 weeks for patients with low serum IL-1Ra levels (P=0.027). The median OS was 38 weeks in patients with a high serum IL-1Ra level, and 62 weeks in patients with a low serum IL-1Ra level (P=0.065). The results of the present study have demonstrated that there was a significant correlation between IL-1Ra levels and NSCLC progression and survival, although the correlation between IL-1Ra levels and the response to treatment was not statistically significant. Therefore, the pre-treatment IL-1Ra level has been identified as a putative prognostic factor for NSCLC.

show abstract

Section: Discussionsupporting

confidence: 91%

“…Inflammation is frequently investigated in the etiology of different cancer types, including thyroid cancer. The immune system is hyperactive in Hashimoto's thyroiditis, and an association between this disease and thyroid cancer has been reported (15).…”

Section: Discussionmentioning

confidence: 99%

Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer

Yiğit

Değirmencioğlu

Uğurlu

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Elevated serum levels of IL-1β correlate with breast cancer recurrence (Mettler et al, 2004). IL-1RA levels are higher in older breast cancer patients whose cancer lack estrogen receptors (Fuksiewicz et al, 2006).…”

Section: Introductionmentioning

confidence: 94%

“…Although there are several markers of disease that are associated with inflammation in breast cancer (Fuksiewicz et al, 2006), few studies have prospectively examined disease and treatment factors that might be related to change in inflammation in response to chemotherapy for breast cancer. Kummel et al (Kummel et al, 2006) examined circulating levels of VEGF (VEGF-A) and VEGF-D (a lymphangiogenic growth factor) (Yamazaki and Morita, 2006), prior to and following adjuvant chemotherapy in patients with positive node breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer

Mills

Ancoli‐Israel

Parker

et al. 2008

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Although chemotherapy for breast cancer can increase inflammation, few studies have examined predictors of this phenomenon. This study examined potential contributions of demographics, disease characteristics, and treatment regimens to markers of inflammation in response to chemotherapy for breast cancer. Thirty-five women with stage I -III-A breast cancer (mean age 50 years) were studied prior to cycle 1 and prior to cycle 4 of anthracycline-based chemotherapy. Circulating levels of inflammatory markers with high relevance to breast cancer were examined, including C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), Interleukin-1 receptor antagonist (IL1-RA), vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule-1 (sICAM-1), Interleukin-(IL-6), soluble P-selectin (sP-selectin), and von Willebrand factor (vWf). Chemotherapy was associated with elevations in VEGF (p≤0.01), sICAM-1 (p≤0.01), sP-selectin (p≤0.02) and vWf (p≤0.05). Multiple regression analysis controlling for age and body mass index (BMI) showed that higher post-chemotherapy levels of inflammation were consistently related to higher prechemotherapy levels of inflammation (p's ≤0.05) as well as to certain disease characteristics. Postchemotherapy IL-6 levels were higher in patients who had larger tumors (p≤0.05) while postchemotherapy VEGF levels were higher in patients who had smaller tumors (p≤0.05). Postchemotherapy sP-selectin levels were highest in women who had received epirubicin, cytoxan, 5fluorouracil chemotherapy (p≤0.01). These findings indicate that chemotherapy treatment can be associated with elevations in certain markers of inflammation, particularly markers of endothelial and platelet activation. Inflammation in response to chemotherapy is most significantly related to inflammation that existed prior to chemotherapy but also potentially to treatment regimen and to certain disease characteristics.

show abstract

“…In 1992, Strieter et al 50 found that IL-8 could promote corneal neovascularization in rabbits. Afterward, the function of IL-8 in tumor development received comprehensive attention, and its effect on promoting tumor angiogenesis was 54 Arenberg et al's 55 study confirmed that inhibiting the expression of IL-8 in SCID mice could reduce the incidence of non-small-cell lung cancer. High expression of IL-8 is closely related to the development of non-small-cell lung cancer; therefore, IL-8 can be used as a biochemical indicator for patients with non-small-cell lung cancer after prognosis.…”

Section: Immunohistochemistrymentioning

confidence: 99%

Preparation, characterization, and evaluation of antitumor effect of Brucea javanica oil cationic nanoemulsions

Liu¹,

Mu²,

Dai³

et al. 2016

IJN

View full text Add to dashboard Cite

The purpose of this study was to prepare Brucea javanica oil cationic nanoemulsions (BJO-CN) with BJO as drug as well as oil phase and chitosan as cationic inducer, to explore the practical suitability of using cationic nanoemulsions for oral delivery of mixed oil, and to test its bioavailability and antitumor effect. BJO-CN was prepared by chitosan solution stirring method and then characterized physicochemically. The obtained BJO-CN had a spherical morphology with a positive zeta potential of 18.9 mV and an average particle size of 42.36 nm, showing high colloidal stability. The drug loading of BJO-CN was 91.83 mg·mL −1 , determined by high-performance liquid chromatography with precolumn derivatization. Pharmacokinetic studies revealed that, compared with BJO emulsion (BJO-E) (the dosage of BJO-CN and BJO-E was equal to 505 mg·kg −1 , calculated by oleic acid), BJO-CN exhibited a significant increase in the area under the plasma drug concentration–time curve over the period of 24 hours and relative bioavailability was 1.6-fold. Furthermore, the antitumor effect of BJO-CN in the orthotopic mouse model of lung cancer was evaluated by recording the median survival time and the weight of lung tissue with tumor, hematoxylin and eosin staining, and immunohistochemical technique. Results of anticancer experiments illustrated that, even though the administrated dosage in the BJO-CN group was half of that in the BJO-E group, BJO-CN exhibited similar antitumor effect to BJO-E. Moreover, BJO-CN had good synergistic effect in combination therapy with vinorelbine. These results suggested that cationic nanoemulsions are an effective and promising delivery system to enhance the oral bioavailability and anticancer effect of BJO.

show abstract

Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients

Abstract: IL-1ra and IL-8 concentrations in serum, together with a lack of estrogen and progesterone receptors in tumor cells, in breast cancer patients older than 50 years could represent additional predictive factors for this disease.

Cited by 25 publications

References 13 publications

Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer

Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer

Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer

Preparation, characterization, and evaluation of antitumor effect of Brucea javanica oil cationic nanoemulsions

Contact Info

Product

Resources

About